Albertsons, Safeway forced to make major pharmacy changes after $900 million ruling

Grocery store pharmacies offer a convenient way to pick up medications while shopping for everyday essentials. However, behind those pharmacy counters are safeguards to protect patients from dangerous prescriptions and the misuse of addictive drugs.

A Washington court has now found that those safeguards repeatedly failed at one of the nation’s largest grocery chains, raising serious questions about how its pharmacies operated for years.

On Nov. 5, King County Superior Court Judge Janet Helson ordered Albertsons Companies to pay $900 million after concluding that the retailer’s pharmacy practices substantially contributed to Washington’s opioid epidemic.

The decision came after a nine-week trial involving Albertsons and its subsidiary, Safeway. The company operates more than 200 pharmacies in Washington under the Albertsons, Safeway, and Haggen brands.

According to the Washington Attorney General’s Office, the ruling includes $800 million to address the opioid crisis, including funding for addiction treatment. The rest is $100 million in civil penalties, plus additional legal fees and costs.

But the financial judgment is only one part of the decision. The court has also ordered substantial changes to how the company’s Washington pharmacies handle certain prescriptions.

Albertsons disagrees with the judgment and is reviewing options, including an appeal.

Judge finds millions of prescriptions carried warning signs

Between 2006 and 2022, Albertsons pharmacies dispensed more than 641 million opioid pills in Washington, according to the court findings.

More than 6.5 million opioid prescriptions, representing approximately 61.6% of those analyzed, carried warning signs suggesting potential misuse or diversion into illegal markets.

The court found that 96% of flagged prescriptions lacked sufficient documentation showing that pharmacists had investigated and resolved those concerns.

More Lawsuits:

Kansas City to pay $900,000 over a Harrison Butker post
A travel company is suing Trump over national park fees
Carl Icahn faces new legal fight over $13 billion deal

The failures extended beyond individual pharmacies. The court found that Albertsons shipped nearly 12,000 internally flagged orders to its Washington pharmacies without canceling a single one or reporting any suspicious orders to the Drug Enforcement Administration.

Warning signs included overlapping prescriptions from different doctors, unusually high dosages, and combinations of medications that could increase the risk of overdose.

The judge also questioned whether the company had sufficiently addressed the problems, finding that some practices continued despite years of scrutiny.

Albertsons had yet to integrate a warning-sign checklist into its pharmacy dispensing software or establish adequate monitoring to ensure pharmacists documented their prescription reviews.

The judge acknowledged that many of these prescriptions likely went to patients with legitimate medical needs. Nevertheless, the failure to investigate and document potential risks created opportunities for improper dispensing and diversion.

The findings also highlighted substantial weaknesses in the company’s controlled-substance monitoring systems.

In one particularly troubling incident, a Safeway employee stole more than 70,000 opioid pills from a North Bend pharmacy over approximately two years. Other cases involved thousands of missing pills at pharmacies in Leavenworth and Olympia.

Albertsons hit with $900 million verdict over pharmacy failures

JHVEPhoto / Getty Images

Albertsons did not adequately staff pharmacies

The court’s findings went beyond prescription records and drug monitoring.

Albertsons’ staffing practices also contributed to the failures, with pharmacists reporting overwhelming workloads and inadequate time to review potentially dangerous prescriptions.

According to the Attorney General’s announcement, employees described exhaustion, missed breaks, and intense pressure to keep pharmacies operating despite insufficient staffing. One pharmacist warned that under such conditions, “mistakes can easily be made to put someone’s life at risk.”

The court concluded that Albertsons prioritized prescription volume and business objectives without providing pharmacists sufficient staffing and tools to meet their legal responsibilities.

However, the judge found no evidence that pharmacists intentionally dispensed improper prescriptions to increase their bonuses.

Albertsons pharmacies face major changes after ruling

The $900 million judgment comes with another significant consequence for Albertsons besides the monetary compensation. A permanent court injunction now requires it to change how its Washington pharmacies dispense and monitor controlled substances.

Under the Nov. 5 court order, Albertsons must strengthen its prescription screening system to identify warning signs of potential opioid misuse.

Pharmacists will be required to investigate and document those concerns before dispensing flagged prescriptions, rather than allowing them to proceed without adequate review.

The requirements extend beyond opioids to certain prescriptions involving benzodiazepines and muscle relaxants, particularly when patients have overlapping prescriptions for medications that can increase overdose risks.

The company must also do this before dispensing controlled substances:

Integrate warning-sign detection into its pharmacy software.
Require pharmacists to review patients’ records in Washington’s Prescription Monitoring Program.

Staffing is another major focus. The court specifically ordered Albertsons to provide enough pharmacy personnel to conduct and document the required safety checks, addressing one of the central failures identified during the trial.

The retailer must also conduct periodic compliance reviews at every Washington pharmacy, take corrective action when violations are identified, and submit annual compliance certifications to the state’s Attorney General for five years.

For customers, these new requirements could mean additional prescription verification, particularly when medications trigger safety warnings. However, the ruling does not mandate pharmacy closures or announce changes to prescription prices.

Albertsons has said it is evaluating its options, including an appeal, but has not confirmed whether it will challenge the judgment.

Albertsons’ opioid troubles go beyond Washington

The judgment comes as Washington deals with the devastating consequences of opioid misuse.

According to evidence reviewed by the court, approximately 7,400 Washington residents died from opioid overdoses between 2022 and 2024.

The Washington State Department of Health’s overdose dashboard tracks the crisis, which has increasingly involved illicit synthetic opioids such as fentanyl. Although overdose deaths declined in 2024 from their 2023 peak, the crisis remains a significant public-health concern.

The opioid concern is not limited to the state, as Albertsons is also facing legal consequences outside Washington.

In April 2026, the company announced a nationwide opioid settlement framework worth approximately $774 million, subject to additional agreements and conditions. Washington was excluded from that arrangement and pursued its lawsuit independently.

In its Oct. 20 SEC filing, Albertsons also disclosed ongoing opioid-related litigation in Texas and Philadelphia, as well as information requests from the U.S. Department of Justice.

Other large retailers have also faced similar legal action in the past. Washington previously reached opioid-related settlements with Walmart (in 2022) and Kroger (in 2024), reflecting the broader scrutiny of pharmacies’ responsibilities in preventing opioid misuse.

Albertsons, meanwhile, disputed the Nov. 5 judgment.

In a statement provided to TheStreet, Albertsons Companies defended its pharmacy operations and expressed disagreement with the judgment.

“Albertsons Companies is disappointed by the court’s ruling and respectfully disagrees with its conclusions. We are reviewing the decision closely and will evaluate all available options, including appeal. We are proud of our pharmacists and their dedication to the patients and communities they serve, and we will continue to support our customers and communities across Washington through responsible pharmacy operations.”